Current and Emerging Second‐Generation Triptans in Acute Migraine Therapy: A Comparative Review

@article{Deleu2000CurrentAE,
  title={Current and Emerging Second‐Generation Triptans in Acute Migraine Therapy: A Comparative Review},
  author={D. Deleu and Y. Hanssens},
  journal={The Journal of Clinical Pharmacology},
  year={2000},
  volume={40}
}
  • D. Deleu, Y. Hanssens
  • Published 2000
  • Medicine
  • The Journal of Clinical Pharmacology
    • Sterile neurogenic inflammation within cephalic tissue, involving vasodilation and plasma protein extravasation, has been proposed as a pathophysiological mechanism in acute migraine. The action of 5‐hydroxytryptamine (5‐HT1B/1D) agonists—so‐called triptans—on receptors located in meningeal arteries (5‐HT1B) and trigeminovascular fiber endings (5‐HT1D) has an inhibitory effect on this neurogenic inflammation. Recently, a series of second‐generation 5‐HT1B/1D agonists (almotriptan, eletriptan… CONTINUE READING
    View on Wiley
    ncbi.nlm.nih.gov
    83 Citations
    Highly Influencial Citations
    3
    Background Citations
    26
    Methods Citations
    1
    83 Citations
    Citation Type

    Citation Type

    Is selective 5‐HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
    • 33
    • PDF
    Eletriptan
    Migraine in the era of precision medicine.
    • 11
    Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment.
    Mechanisms of action of the 5-HT1B/1D receptor agonists.
    • 134
    • PDF
    Therapies in development for the treatment of migraine
    • H. Mucke
    • Medicine
    • Expert opinion on investigational drugs
    • 2002
    • 3
    Triptans and CNS Side-Effects
    • 58
    Triptans in migraine. A review of side effects, improvement and recurrence
    Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence‐based pharmacotherapeutic case report
    • 2
    • PDF
    Renal Infarction During the Use of Rizatriptan and Zolmitriptan: Two Case Reports
    • 17

    References

    SHOWING 1-10 OF 165 REFERENCES
    Acute migraine therapy: the newer drugs
    • 53
    Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
    • 98
    Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study
    • 54
    Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
    • 10
    Pre-clinical pharmacology of zolmitriptan (Zomig™; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine
    • G. Martin
    • Medicine
    • Cephalalgia : an international journal of headache
    • 1997
    • 71
    Sumatriptan in the treatment of migraine
    • 27
    The Long‐term Tolerability and Efficacy of Oral Zolmitriptan (Zomig, 31X90) in the Acute Treatment of Migraine. An International Study
    • 88
    Rizatriptan has central antinociceptive effects against durally evoked responses.
    • 146
    Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5‐hydroxy‐tryptamine (5‐HT1B/1D) receptors
    • 104
    5‐HT1 receptors in migraine pathophysiology and treatment
    • 80